Unigene Labs Inc (UGNEQ) 0.0002 $UGNEQ Global P
Post# of 273249
Posted On: 06/22/2016 6:09:53 PM
Unigene Labs Inc (UGNEQ) 0.0002 $UGNEQ
Global Post Menopausal Osteoporosis Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbs2h3/post_menopausal) has announced the addition of the "Post Menopausal Osteoporosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Post Menopausal Osteoporosis Overview - Therapeutics Development - Pipeline Products for Post Menopausal Osteoporosis - Overview - Pipeline Products for Post Menopausal Osteoporosis - Comparative Analysis - Post Menopausal Osteoporosis - Therapeutics under Development by Companies - Post Menopausal Osteoporosis - Therapeutics under Investigation by Universities/Institutes - Post Menopausal Osteoporosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Post Menopausal Osteoporosis - Products under Development by Companies - Post Menopausal Osteoporosis - Products under Investigation by Universities/Institutes - Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development - Amgen Inc. - Chronos Therapeutics Limited - Eli Lilly and Company - Hanmi Pharmaceuticals, Co. Ltd. - Ligand Pharmaceuticals, Inc. - Merck & Co., Inc. - Oncobiologics, Inc. - Paras Biopharmaceuticals Finland Oy - Pfizer Inc. - Radius Health, Inc. - Richter-Helm BioTec GmbH & Co. KG - Unigene Laboratories, Inc. (Inactive) For more information visit http://www.researchandmarkets.com/research/lb...menopausal
RDUS: 35.67 (-0.22), PFE: 34.47 (-0.28), MRK: 57.04 (+0.79), AMGN: 149.81 (+0.39), LLY: 73.07 (+0.50)
Global Post Menopausal Osteoporosis Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbs2h3/post_menopausal) has announced the addition of the "Post Menopausal Osteoporosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Post Menopausal Osteoporosis Overview - Therapeutics Development - Pipeline Products for Post Menopausal Osteoporosis - Overview - Pipeline Products for Post Menopausal Osteoporosis - Comparative Analysis - Post Menopausal Osteoporosis - Therapeutics under Development by Companies - Post Menopausal Osteoporosis - Therapeutics under Investigation by Universities/Institutes - Post Menopausal Osteoporosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Post Menopausal Osteoporosis - Products under Development by Companies - Post Menopausal Osteoporosis - Products under Investigation by Universities/Institutes - Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development - Amgen Inc. - Chronos Therapeutics Limited - Eli Lilly and Company - Hanmi Pharmaceuticals, Co. Ltd. - Ligand Pharmaceuticals, Inc. - Merck & Co., Inc. - Oncobiologics, Inc. - Paras Biopharmaceuticals Finland Oy - Pfizer Inc. - Radius Health, Inc. - Richter-Helm BioTec GmbH & Co. KG - Unigene Laboratories, Inc. (Inactive) For more information visit http://www.researchandmarkets.com/research/lb...menopausal
RDUS: 35.67 (-0.22), PFE: 34.47 (-0.28), MRK: 57.04 (+0.79), AMGN: 149.81 (+0.39), LLY: 73.07 (+0.50)
(0)
(0)Scroll down for more posts ▼